- Report
- October 2024
- 187 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- March 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 131 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 129 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 138 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- February 2021
- 420 Pages
United States
From €2184EUR$2,400USD£1,873GBP
- Report
- September 2021
- 40 Pages
China
From €2366EUR$2,600USD£2,029GBP
- Report
- July 2023
- 129 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Report
- December 2023
- 117 Pages
Global
From €13647EUR$14,995USD£11,699GBP
- Report
- March 2019
- 16 Pages
Global
€9101EUR$10,000USD£7,802GBP
- Report
- February 2024
- 75 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Book
- February 2024
- 592 Pages

Escitalopram is a selective serotonin reuptake inhibitor (SSRI) used to treat mental disorders such as depression, anxiety, and obsessive-compulsive disorder (OCD). It is the S-enantiomer of the racemic drug citalopram, and is marketed under the brand names Lexapro and Cipralex. Escitalopram is generally well tolerated and has fewer side effects than other SSRIs. It is also used off-label to treat premenstrual dysphoric disorder, panic disorder, and social anxiety disorder.
The escitalopram market is highly competitive, with several major players offering generic and branded versions of the drug. Companies such as Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals are among the leading manufacturers of generic escitalopram. Branded versions of the drug are marketed by Forest Laboratories, Lundbeck, and H. Lundbeck A/S. Show Less Read more